Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J. appl. oral sci ; 25(6): 631-640, Nov.-Dec. 2017. tab, graf
Article in English | LILACS, BBO | ID: biblio-893662

ABSTRACT

Abstract Objectives: The primary purpose of this study was to examine the effects of triethylene glycol dimethacrylate (TEGDMA) on odontoclastic differentiation in the dental pulp tissue. Material and Methods: The effects of different TEGDMA dosages on the odontoclastic differentiation capability of dental pulp cells were analyzed in vitro using the following methodologies: i) flow cytometry and tartrate-resistant acid phosphatase (TRAP) staining; ii) apoptotic effects using Annexin V staining; iii) mRNA expression of osteoprotegerin (OPG) and receptor activator of nuclear factor (NF)-kB ligand (RANKL) genes by quantitative Real-time PCR (qRT-PCR); and iv) OPG and RANKL protein expression by enzyme-linked immunosorbent assay (ELISA). Results: TEGDMA caused relatively less odontoclastic differentiation in comparison with the control group; however, odontoclastic differentiation augmented with increasing doses of TEGDMA (p<0.05). The mRNA and protein expression of OPG was lower in TEGDMA treated pulp cells than in the control group (p<0.05). While the mRNA expression of RANKL remained unchanged compared to the control group (p>0.05), its protein expression was higher than the control group (p<0.05). In addition, TEGDMA increased the apoptosis of dental pulp cells dose dependently. Conclusions: TEGDMA reduced the odontoclastic differentiation ability of human dental pulp cells. However, odontoclastic differentiation ratios increased proportionally with the increasing dose of TEGDMA.


Subject(s)
Humans , Polyethylene Glycols/pharmacology , Polymethacrylic Acids/pharmacology , Cell Differentiation/drug effects , Dental Pulp/drug effects , Tartrate-Resistant Acid Phosphatase/drug effects , Enzyme-Linked Immunosorbent Assay , Lipopolysaccharide Receptors/metabolism , Dental Pulp/cytology , RANK Ligand/metabolism , Real-Time Polymerase Chain Reaction , Flow Cytometry
2.
Journal of Korean Medical Science ; : 145-150, 2015.
Article in English | WPRIM | ID: wpr-141165

ABSTRACT

Differentiated HL-60 is an effector cell widely used for the opsonophagocytic-killing assay (OPKA) to measure efficacy of pneumococcal vaccines. We investigated the correlation between phenotypic expression of immunoreceptors and phagocytic ability of HL-60 cells differentiated with N,N-dimethylformamide (DMF), all-trans retinoic acid (ATRA), or 1alpha, 25-dihydroxyvitamin D3 (VitD3) for 5 days. Phenotypic change was examined by flow cytometry with specific antibodies to CD11c, CD14, CD18, CD32, and CD64. Apoptosis was determined by flow cytometry using 7-aminoactinomycin D. Function was evaluated by a standard OPKA against serotype 19F and chemiluminescence-based respiratory burst assay. The expression of CD11c and CD14 gradually increased upon exposure to all three agents, while CD14 expression increased abruptly after VitD3. The expression of CD18, CD32, and CD64 increased during differentiation with all three agents. Apoptosis remained less than 10% until day 3 but increased after differentiation by DMF or ATRA. Differentiation with ATRA or VitD3 increased the respiratory burst after day 4. DMF differentiation showed a high OPKA titer at day 1 which sustained thereafter while ATRA or VitD3-differentiated cells gradually increased. Pearson analysis between the phenotypic changes and OPKA titers suggests that CD11c might be a useful differentiation marker for HL-60 cells for use in pneumococcal OPKA.


Subject(s)
Humans , Antibodies, Bacterial/immunology , CD11c Antigen/metabolism , Lipopolysaccharide Receptors/metabolism , CD18 Antigens/metabolism , Apoptosis/immunology , Biological Assay , Cell Differentiation , Cell Line, Tumor , Cholecalciferol/pharmacology , Dimethylformamide/pharmacology , Flow Cytometry , HL-60 Cells , Phagocytosis/immunology , Pneumococcal Vaccines/immunology , Receptors, IgG/metabolism , Receptors, Immunologic/biosynthesis , Respiratory Burst/immunology , Streptococcus pneumoniae/immunology , Tretinoin/pharmacology
3.
Journal of Korean Medical Science ; : 145-150, 2015.
Article in English | WPRIM | ID: wpr-141164

ABSTRACT

Differentiated HL-60 is an effector cell widely used for the opsonophagocytic-killing assay (OPKA) to measure efficacy of pneumococcal vaccines. We investigated the correlation between phenotypic expression of immunoreceptors and phagocytic ability of HL-60 cells differentiated with N,N-dimethylformamide (DMF), all-trans retinoic acid (ATRA), or 1alpha, 25-dihydroxyvitamin D3 (VitD3) for 5 days. Phenotypic change was examined by flow cytometry with specific antibodies to CD11c, CD14, CD18, CD32, and CD64. Apoptosis was determined by flow cytometry using 7-aminoactinomycin D. Function was evaluated by a standard OPKA against serotype 19F and chemiluminescence-based respiratory burst assay. The expression of CD11c and CD14 gradually increased upon exposure to all three agents, while CD14 expression increased abruptly after VitD3. The expression of CD18, CD32, and CD64 increased during differentiation with all three agents. Apoptosis remained less than 10% until day 3 but increased after differentiation by DMF or ATRA. Differentiation with ATRA or VitD3 increased the respiratory burst after day 4. DMF differentiation showed a high OPKA titer at day 1 which sustained thereafter while ATRA or VitD3-differentiated cells gradually increased. Pearson analysis between the phenotypic changes and OPKA titers suggests that CD11c might be a useful differentiation marker for HL-60 cells for use in pneumococcal OPKA.


Subject(s)
Humans , Antibodies, Bacterial/immunology , CD11c Antigen/metabolism , Lipopolysaccharide Receptors/metabolism , CD18 Antigens/metabolism , Apoptosis/immunology , Biological Assay , Cell Differentiation , Cell Line, Tumor , Cholecalciferol/pharmacology , Dimethylformamide/pharmacology , Flow Cytometry , HL-60 Cells , Phagocytosis/immunology , Pneumococcal Vaccines/immunology , Receptors, IgG/metabolism , Receptors, Immunologic/biosynthesis , Respiratory Burst/immunology , Streptococcus pneumoniae/immunology , Tretinoin/pharmacology
4.
Experimental & Molecular Medicine ; : e8-2013.
Article in English | WPRIM | ID: wpr-199828

ABSTRACT

We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8+ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.


Subject(s)
Animals , Mice , Acute-Phase Proteins/metabolism , Adaptor Proteins, Vesicular Transport/metabolism , Lipopolysaccharide Receptors/metabolism , Bone Marrow Cells/cytology , CD8-Positive T-Lymphocytes/immunology , Carrier Proteins/metabolism , Cell Differentiation/drug effects , Cell Nucleus/drug effects , Cell Proliferation/drug effects , Cytokines/biosynthesis , Dendritic Cells/cytology , Enzyme Activation/drug effects , Lymphocyte Activation/drug effects , Membrane Glycoproteins/metabolism , Mice, Inbred C57BL , Mice, Knockout , Mitogen-Activated Protein Kinases/metabolism , Myeloid Differentiation Factor 88/metabolism , NF-kappa B/metabolism , Neoplasms/immunology , Pectins/pharmacology , Phenotype , Protein Transport/drug effects , Receptors, Chemokine/metabolism , Signal Transduction/drug effects , T-Lymphocytes, Cytotoxic/cytology , Toll-Like Receptor 4/agonists
5.
Clinical and Molecular Hepatology ; : 337-346, 2012.
Article in English | WPRIM | ID: wpr-15278

ABSTRACT

Because of the anatomical position and its unique vascular system, the liver is susceptible to the exposure to the microbial products from the gut. Although large amount of microbes colonize in the gut, translocation of the microbes or microbial products into the liver and systemic circulation is prevented by gut epithelial barrier function and cleansing and detoxifying functions of the liver in healthy subjects. However, when the intestinal barrier function is disrupted, large amount of bacterial products can enter into the liver and systemic circulation and induce inflammation through their receptors. Nowadays, there have been various reports suggesting the role of gut flora and bacterial translocation in the pathogenesis of chronic liver disease and portal hypertension. This review summarizes the current knowledge about bacterial translocation and its contribution to the pathogenesis of chronic liver diseases and portal hypertension.


Subject(s)
Humans , Lipopolysaccharide Receptors/metabolism , Bacterial Translocation , Gastrointestinal Tract/microbiology , Hypertension, Portal/metabolism , Liver/metabolism , Liver Cirrhosis/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Toll-Like Receptors/metabolism
6.
Experimental & Molecular Medicine ; : 126-133, 1999.
Article in English | WPRIM | ID: wpr-36359

ABSTRACT

To characterize the TGF-beta1 response of monocytic leukemia cells, we analyzed the effects of TGF-beta1 on cell proliferation, differentiation, and apoptosis of human monoblastic U937 cells. Treatment of cells with TGF-beta1 in the absence of growth factors significantly enhanced cell viability. Flow cytometric analysis of DNA content and CD14 expression revealed that TGF-beta1 does not affect cell proliferation and differentiation. Consistent with these results was the finding that no transcriptional induction of Cdk inhibitors such as p21Waf1, p15Ink4b, and p27Kip1 was detected following TGF-beta1 treatment. Interestingly, however, pretreatment of TGF-beta1 significantly inhibited Fas-, DNA damage-, and growth factor deprivation-induced apoptosis. This antiapoptotic effect was totally abrogated by anti-TGF-beta1 antibody. Quantitative RT-PCR analysis demonstrated a dose- and time-dependent transcriptional up-regulation of Bcl-X(L), suggesting its implication in the TGF-1-mediated antiapoptotic pathway. We also observed elevated expression of c-Fos and PTEN/MMAC1. But, no detectable change was recognized in expression of c-Jun, Fas, Fadd, Fap-1, Bcl-2, and Bax. Taken together, our study shows that TGF-beta1 enhancement of cellular viability is associated with its antiapoptotic effect, which may result from the transcriptional up-regulation of Bcl-X(L).


Subject(s)
Humans , Lipopolysaccharide Receptors/metabolism , fas Receptor/metabolism , Apoptosis/drug effects , Cell Cycle/drug effects , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Survival/drug effects , DNA/analysis , DNA Damage , Gene Expression Regulation, Neoplastic/genetics , Genes, Tumor Suppressor/genetics , Leukemia, Myeloid/genetics , Neoplasm Proteins/metabolism , Phosphoric Monoester Hydrolases/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/biosynthesis , RNA, Messenger/metabolism , Receptors, Antigen, T-Cell/genetics , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Transforming Growth Factor beta/pharmacology , U937 Cells , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL